The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Phage Therapy Pharmacology
Abstract
Phage therapy--application of bacteria-specific viruses to reduce densities of pathogenic or nuisance bacteria--is a two-step process involving phage penetration to target bacteria followed by bacteria killing. Any analysis of these steps is inherently ecological as they represent phage-environment interactions, i.e., between phages and bacteria as well as between phages and body tissues. In considering phages more generically, as selectively toxic antibacterial agents employed to treat bacterial infections, the term "ecology" may be fairly cleanly replaced with the term "pharmacology". Pharmacology, in turn, may be distinguished into two major components: pharmacokinetics and pharmacodynamics. Pharmacokinetics is explicitly a description of the body's impact on a drug (e.g., movement through and between body compartments) whereas pharmacodynamics is a description of a drug's impact on the body. "Body" includes both body tissues and microbial flora, so an important component of antibacterial pharmacodynamics is inhibition of the growth of target bacteria. Our guiding premise is that phage therapy may be rationally improved through a better understanding of phage pharmacokinetics and pharmacodynamics. Our primary conclusions are (i) that the principle advantages of phages, over antibiotics, are the former's relative safety and ease of discovery; (ii) that phage therapy efficacy is highly dependent on attaining relatively high phage "killing titers"; (iii) that attainment of sufficient titers solely via in situ phage replication should, in some or many circumstances, not be counted upon; and (iv) that phage replication nonetheless may provide a "margin of safety" toward attaining phage therapy efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibiotics for Emerging Pathogens
Fischbach, M. A., & Walsh, C. T. (2009) · Science · doi:10.1126/science.1176667 · Cited by 1,777
Pros and cons of phage therapy
Loc-Carrillo, C., & Abedon, S. T. (2011) · Bacteriophage · doi:10.4161/bact.1.2.14590 · Cited by 1,020
Self-citationPhage treatment of human infections
Abedon, S. T., Kuhl, S. J., Blasdel, B. G., & Kutter, E. M. (2011) · Bacteriophage · doi:10.4161/bact.1.2.15845 · Cited by 980
Self-citationWright, A., Hawkins, C. H., Änggård, E. E., & Harper, D. R. (2009) · Clinical Otolaryngology · doi:10.1111/j.1749-4486.2009.01973.x · Cited by 864
Bacteriophage Host Range and Bacterial Resistance
Hyman, P., & Abedon, S. T. (2010) · Advances in Applied Microbiology · doi:10.1016/s0065-2164(10)70007-1 · Cited by 819
Self-citation5500 Phages examined in the electron microscope
Ackermann, H.-W. (2007) · Archives of Virology · doi:10.1007/s00705-006-0849-1 · Cited by 752
Phage Therapy in Clinical Practice: Treatment of Human Infections
Kutter, E., De Vos, D., Gvasalia, G., Alavidze, Z., Gogokhia, L., Kuhl, S., & Abedon, S. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725401 · Cited by 670
Self-citationHuman Volunteers Receiving Escherichia coli Phage T4 Orally: a Safety Test of Phage Therapy
Bruttin, A., & Brüssow, H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.7.2874-2878.2005 · Cited by 563
Population and evolutionary dynamics of phage therapy
Levin, B. R., & Bull, J. J. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro822 · Cited by 511
Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial
Rhoads, D. D., Wolcott, R. D., Kuskowski, M. A., Wolcott, B. M., Ward, L. S., & Sulakvelidze, A. (2009) · Journal of Wound Care · doi:10.12968/jowc.2009.18.6.42801 · Cited by 468
The causes of intestinal dysbiosis: a review.
Hawrelak, J. A., & Myers, S. P. (2004) · PubMed · Cited by 454
Phage Choice, Isolation, and Preparation for Phage Therapy
Gill, J., & Hyman, P. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725311 · Cited by 441
Abedon, S. T. (2011) · Bacteriophage · doi:10.4161/bact.1.1.13980 · Cited by 410
Self-citationThe Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States
Schackman, B. R., Gebo, K. A., Walensky, R. P., Losina, E., Muccio, T., Sax, P. E., Weinstein, M. C., Seage, G. R., Moore, R. D., & Freedberg, K. A. (2006) · Medical Care · doi:10.1097/01.mlr.0000228021.89490.2a · Cited by 410
Bacteriophage for Biocontrol of Foodborne Pathogens: Calculations and Considerations
Hagens, S., & Loessner, M. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725429 · Cited by 366
Practical Methods for Determining Phage Growth Parameters
Hyman, P., & Abedon, S. T. (2009) · Methods in Molecular Biology · doi:10.1007/978-1-60327-164-6_18 · Cited by 327
Self-citationPhage Therapy of Pseudomonas aeruginosa Infection in a Mouse Burn Wound Model
McVay, C. S., Velásquez, M., & Fralick, J. A. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01028-06 · Cited by 306
Murray, A., & Jackson, G. (1992) · Marine Ecology Progress Series · doi:10.3354/meps089103 · Cited by 297
O’Flaherty, S., Ross, R. P., Meaney, W. J., Fitzgerald, G. F., Elbreki, M., & Coffey, A. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.4.1836-1842.2005 · Cited by 243
Understanding Bacteriophage Therapy as a Density-dependent Kinetic Process
PAYNE, R. J. H., & JANSEN, V. A. A. (2001) · Journal of Theoretical Biology · doi:10.1006/jtbi.2000.2198 · Cited by 233
Overcoming the Phage Replication Threshold: a Mathematical Model with Implications for Phage Therapy
Kasman, L. M., Kasman, A., Westwater, C., Dolan, J., Schmidt, M. G., & Norris, J. S. (2002) · Journal of Virology · doi:10.1128/jvi.76.11.5557-5564.2002 · Cited by 221
Phage Therapy for Plant Disease Control
Balogh, B., Jones, J., Iriarte, F., & Momol, M. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725302 · Cited by 220
Phage therapy: The peculiar kinetics of self-replicating pharmaceuticals
Payne, R. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.109520 · Cited by 216
Pharmacokinetic Principles of Bacteriophage Therapy
Payne, R. J. H., & Jansen, V. A. A. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342040-00002 · Cited by 207
Biotechnological challenges of phage therapy
Skurnik, M., Pajunen, M., & Kiljunen, S. (2007) · Biotechnology Letters · doi:10.1007/s10529-007-9346-1 · Cited by 203
Toxicity of antiretroviral therapy and implications for drug development
Carr, A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1151 · Cited by 191
The evolution of phage lysis timing
Wang, I.-N., Dykhuizen, D. E., & Slobodkin, L. B. (1996) · Evolutionary Ecology · doi:10.1007/bf01237884 · Cited by 183
Hawkins, C., Harper, D., Burch, D., Änggård, E., & Soothill, J. (2010) · Veterinary Microbiology · doi:10.1016/j.vetmic.2010.05.014 · Cited by 183
Optimal Drug Synergy in Antimicrobial Treatments
Torella, J. P., Chait, R., & Kishony, R. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000796 · Cited by 162
Working with bacteriophages: common techniques and methodological approaches
Carlson, K. (2005) · Cited by 160
Biotechnological exploitation of bacteriophage research
Petty, N. K., Evans, T. J., Fineran, P. C., & Salmond, G. P. C. (2006) · Trends in biotechnology · doi:10.1016/j.tibtech.2006.11.003 · Cited by 156
Goodridge, L. D. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725348 · Cited by 155
Abedon, S. T. (2011) · Advances in applied microbiology · doi:10.1016/b978-0-12-387044-5.00001-7 · Cited by 153
Self-citationGuttman, B. S., Raya, R. R., & Kutter, E. M. (2004) · CRC Press eBooks · doi:10.1201/9780203491751.ch3 · Cited by 135
Drug Interactions of Medications Commonly Used in Diabetes
Triplitt, C. L. (2006) · Diabetes Spectrum · doi:10.2337/diaspect.19.4.202 · Cited by 133
Chapter 1 Phage Evolution and Ecology
Abedon, S. T. (2009) · Advances in applied microbiology · doi:10.1016/s0065-2164(08)01001-0 · Cited by 129
Self-citationBacteriophage therapy for the treatment of infections.
Górski, A., Międzybrodzki, R., Borysowski, J., et al. (2009) · PubMed · Cited by 129
Synergism between Streptomycin and Penicillin: A Proposed Mechanism
Plötz, P. H., & Davis, B. D. (1962) · Science · doi:10.1126/science.135.3508.1067 · Cited by 100
Nishikawa, H., Yasuda, M., Uchiyama, J., Rashel, M., Maeda, Y., Takemura, I., Sugihara, S., Ujihara, T., Shimizu, Y., Shuin, T., et al. (2008) · Archives of Virology · doi:10.1007/s00705-007-0031-4 · Cited by 88
Antagonism between penicillin and erythromycin against Streptococcus pneumoniae in vitro and in vivo
Johansen, H., Jensen, T. G., Dessau, R. B., Lundgren, B., & Frimodt-Moller, N. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.6.973 · Cited by 73
Pouillot, F., Blois, H., & Iris, F. (2010) · Biosecurity and Bioterrorism Biodefense Strategy Practice and Science · doi:10.1089/bsp.2009.0057 · Cited by 64
The proportional lack of archaeal pathogens: Do viruses/phages hold the key?
Gill, E. E., & Brinkman, F. S. L. (2011) · BioEssays · doi:10.1002/bies.201000091 · Cited by 52
Phage Therapy: Emergent Property Pharmacology
Abedon, A. J. C. S. T. (2012) · Journal of Bioanalysis & Biomedicine · doi:10.4172/1948-593x.s6-002 · Cited by 45
Optimal bacteriophage mutation rates for phage therapy
Kysela, D. T., & Turner, P. E. (2007) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2007.08.007 · Cited by 35
Industrial and Regulatory Issues in Bacteriophage Applications in Food Production and Processing
Sulakvelidze, A., & Pasternack, G. R. (2014) · ASM Press eBooks · doi:10.1128/9781555816629.ch15 · Cited by 22
Bacteriophage Therapy: Past and Present
Kutter, E. M. (2009) · Elsevier eBooks · doi:10.1016/b978-012373944-5.00021-3 · Cited by 17
Ackermann, H.-W. (2011) · Bacteriophage · doi:10.4161/bact.1.1.14354 · Cited by 11
Treating Bipolar Disorder: Monotherapy Versus Combination Therapy
Ketter, T. A. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.7128br4c.e42 · Cited by 9
Cited by
Pros and cons of phage therapy
Loc-Carrillo, C., & Abedon, S. T. (2011) · Bacteriophage · doi:10.4161/bact.1.2.14590 · Cited by 1,020
Self-citationPhage treatment of human infections
Abedon, S. T., Kuhl, S. J., Blasdel, B. G., & Kutter, E. M. (2011) · Bacteriophage · doi:10.4161/bact.1.2.15845 · Cited by 980
Self-citationPhage Cocktails and the Future of Phage Therapy
Chan, B. K., Abedon, S. T., & Loc-Carrillo, C. (2013) · Future Microbiology · doi:10.2217/fmb.13.47 · Cited by 914
Self-citationPhage Therapy in Clinical Practice: Treatment of Human Infections
Kutter, E., De Vos, D., Gvasalia, G., Alavidze, Z., Gogokhia, L., Kuhl, S., & Abedon, S. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725401 · Cited by 670
Self-citationKhan Mirzaei, M., & Nilsson, A. S. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118557 · Cited by 516
Metadata
- Authors
- Abedon, S., & Thomas-Abedon, C.
- Venue
- Current Pharmaceutical Biotechnology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2010-01-01
- Volume
- 11
- Issue
- 1
- Pages
- 28-47
- ISSN
- 1389-2010 (ISSN-L)
- OpenAlex
- W2037689374
- Cited by
- 284
- References
- 49
- FWCI
- 9.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.